Evolent Health, Inc Class A (EVH) Covered Calls

Evolent Health, Inc. (EVH) is a specialty care management company that uses a technology-driven platform to improve health outcomes for patients with complex conditions. In 2026, the company is executing a massive strategic pivot toward oncology, which is projected to account for 65% of total revenue. By integrating AI into its "Performance Suite" and specialized care workflows, Evolent aims to reduce medical costs and eliminate administrative burdens for payers and providers.

You can sell covered calls on Evolent Health, Inc Class A to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for EVH (prices last updated Tue 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Evolent Health (EVH) specializes in high-cost specialty care management, focusing on oncology, cardiology, and musculoskeletal (MSK) health. Its primary revenue driver is the Performance Suite, where Evolent takes clinical and financial responsibility for a specific patient population. As of April 2026, the company is managing a surge in new revenue following a $550 million contract expansion with Highmark and a major Aetna deal, bringing its 2026 revenue guidance to a midpoint of $2.5 billion.

The company is currently navigating a period of "investment for scale." While Q4 2025 earnings beat estimates ($0.08 EPS vs $0.06 expected), the stock has faced volatility in early 2026 due to start-up costs from new contracts and a $40 million headwind from declining ACA exchange membership. Management is countering these pressures through "Operational AI"—integrating machine learning into back-office functions to drive toward a target 2026 Adjusted EBITDA of $110 million–$140 million.

Competitive Landscape

Evolent operates in the specialty value-based care market, differentiating itself through its "agnostic" platform that works across multiple payers and providers. It competes against health plan in-house solutions and specialized health-tech firms. In the options market, EVH is a high-volatility name (implied volatility often exceeding 100% in early 2026) due to its high leverage and the "lumpy" nature of large-scale contract implementations.

1. UnitedHealth Group Inc.: The primary industry benchmark; its Optum segment is both a major competitor and a standard-setter for specialty care.
2. Health Catalyst, Inc.: A key peer in the healthcare data analytics and value-based care technology sector.
3. Elevance Health, Inc.: A major payer peer whose in-house care management strategies compete with Evolent's external services.
4. Alignment Healthcare, Inc.: A peer in the Medicare Advantage and value-based care space with an active options chain.
5. agilon health, inc.: A direct peer in the value-based primary care and specialty integration market.

Strategic Outlook and Innovation

Evolent’s 2026 outlook is defined by its "Oncology-First" strategy. Following the 2025 divestiture of its primary care business, the company is now a pure-play specialty manager. Innovation centers on the Identifi® platform, which in 2026 uses AI to proactively identify oncology patients who would benefit from palliative care or clinical trial enrollment, significantly reducing end-of-life medical spend.

Financially, 2026 is a year of deleveraging. After an oversubscribed $145 million convertible note offering in late 2025, the company is focused on paying down high-interest debt and reaching a long-term target of 2.0x net leverage. Investors in April 2026 are looking ahead to the May 7 earnings call to confirm if the $150 million EBITDA run-rate projected for Q4 remains on track. Despite near-term margin pressure from rapid growth, Evolent remains a dominant player in the $50 billion specialty care addressable market.

Want more examples? EVEX Covered Calls | EVLV Covered Calls